Gibraltar Industries Inc. (ROCK) Drops 5.27% on January 21

Equities Staff |

Gibraltar Industries Inc. (ROCK) was one of the Russell 2000's biggest losers for Thursday January 21 as the stock slid 5.27% to $20.33, a loss of $-1.13 per share. Starting at an opening price of $21.52 a share, the stock traded between $20.28 and $21.63 over the course of the trading day. Volume was 152,556 shares over 1,614 trades, against an average daily volume of 283,155 shares and a total float of 31.04 million.

The losses send Gibraltar Industries Inc. down to a market cap of $631.05 million. In the last year, Gibraltar Industries Inc. has traded between $27.89 and $13.44, and its 50-day SMA is currently $24.80 and 200-day SMA is $20.34.

Gibraltar Industries Inc is a manufacturer & distributor of products for the building and industrial markets. Its products provide structural and architectural enhancements for residential homes, other commercial and professional buildings.

Gibraltar Industries Inc. is based out of Buffalo, NY and has some 2,416 employees. Its CEO is Frank Heard.

For a complete fundamental analysis analysis of Gibraltar Industries Inc., check out Equities.com’s Stock Valuation Analysis report for ROCK. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Pinterest

Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…

Snapchat

Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…